Nestle is using artificial intelligence and nutritional science to develop products for the millions of Americans taking GLP-1 weight-loss drugs such as Ozempic and Wegovy, aiming to turn the rise of …
The US adult obesity rate fell to 36.4 percent in 2026, down from a peak of 39.9 percent in 2022, according to a Gallup report, while the share of adults taking GLP-1 drugs for weight loss rose from 3…
The August issue of The Highlight features a cover story by Dylan Scott on the persistent stigma surrounding GLP-1 drugs like Ozempic, Wegovy, and Mounjaro, despite their popularity. Other articles in…
Researchers at Stanford Medicine used artificial intelligence to identify BRP (BRINP2-related peptide), a naturally occurring molecule that reduced food intake and body weight in mice and pigs without…
Cyber extortion group FulcrumSec claimed on Tuesday to have stolen over a terabyte of data from pharmaceutical giant Novo Nordisk and attempted a $25 million extortion. The group said it is now explor…
GLP-1 drug use peaks in middle age, with 22% of adults aged 50-64 taking them, then drops sharply to 9% at age 65 due to Medicare's ban on covering weight-loss medications. The overall adult usage rat…
Novo Nordisk disclosed a cyberattack on its systems, with the company investigating the incident and working to contain the breach. The announcement came as the UK’s medicines regulator granted approv…